Human hepatitis B virus (HBV) is characterized by a high species specificity and a distinct liver tropism. Within the liver, HBV replication occurs in differentiated and polarized hepatocytes. Accordingly, the in vitro HBV infection of primary human hepatocytes (PHHs) and the human hepatoma cell line, HepaRG, is restricted to differentiated, hepatocyte-like cells. Though preparations of PHH contain up to 100% hepatic cells, cultures of differentiated HepaRG cells are a mixture of hepatocyte-like and biliary-like epithelial cells. We used PHH and HepaRG cells and compared the influence of virus inoculation dose, cell differentiation, and polarization on productive HBV infection. At multiplicities of genome equivalents (mge) >8,000, almost 100% of PHHs could be infected. In contrast, only a subset of HepaRG cells stained positive for HBcAg at comparable or even higher mge. Infection predominantly occurred at the edges of islands of hepatocyte-like HepaRG cells. This indicates a limited accessibility of the HBV receptor, possibly as a result of its polar sorting. Multidrug resistance protein 2 (MRP2), a marker selectively transported to the apical (i.e., canalicular) cell membrane, revealed two polarization phenotypes of HepaRG cells. HBV infection within the islands of hepatocyte-like HepaRG cells preferentially occurred in cells that resemble PHH, exhibiting canalicular structures. However, disruption of cell-cell junctions allowed the additional infection of cells that do not display a PHH-like polarization. Conclusion: HBV enters hepatocytes via the basolateral membrane. This model, at least partially, explains the difference of PHH and HepaRG cells in infection efficacy, provides insights into natural HBV infection, and establishes a basis for optimization of the HepaRG infection system. (HEPATOLOGY 2012;55:373-383) H uman hepatitis B virus (HBV), a small, enveloped DNA virus, is the prototypic member of the family, hepadnaviridae, causing acute and persistant liver infections.1 Currently, 360 million people are chronically infected with HBV and are, consequently, prone to developing progressive liver diseases, such as cirrhosis or hepatocellular carcinoma. Hepadnaviruses exhibit a pronounced liver tropism and a narrow host range.2 HBV predominantly infects and replicates in hepatocytes, but virus-specific antigens and nucleic acids have also been found in a number of nonhepatic tissues, including kidney, pancreas, and peripheral blood mononuclear cells.3 However, whether replication in extrahepatic tissues contributes to virus propagation is unclear.4,5 The preference for replication in the liver can only partially be explained by hepatocyte-specific transcription factors.6 Further liver specificity occurs at the stage of early infection, because the differentiation state of HepaRG cells and primary hepatocytes is a prerequisite for the expression of an HBVpreS1-specific receptor and subsequent infection (Meier et al., manuscript in preparation).